The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

Antibody-drug conjugates (ADC) are a novel way to deliver potent cytotoxic compounds to cells expressing a specific antigen. Four ADC targeting CD19, including SAR3419 (coltuximab ravtansine), have entered clinical development. Here, we present huB4-DGN462, a novel ADC based on the SAR3419 anti-CD19...

Descripció completa

Dades bibliogràfiques

Autors principals:	Stuart W. Hicks, Chiara Tarantelli, Alan Wilhem, Eugenio Gaudio, Min Li, Alberto J. Arribas, Filippo Spriano, Roberta Bordone, Luciano Cascione, Katharine C. Lai, Qifeng Qiu, Monica Taborelli, Davide Rossi, Georg Stussi, Emanuele Zucca, Anastasios Stathis, Callum M. Sloss, Francesco Bertoni
Format:	Artigo
Idioma:	Inglês
Publicat:	Ferrata Storti Foundation 2019-08-01
Col·lecció:	Haematologica
Accés en línia:	https://haematologica.org/article/view/9012
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!